Endurance Wealth Management, Inc. Atreca, Inc. Transaction History

Endurance Wealth Management, Inc.

$731 Million
Q2 2023

A detailed history of Endurance Wealth Management, Inc. transactions in Atreca, Inc. stock. As of the latest transaction made, Endurance Wealth Management, Inc. holds 10,600 shares of BCEL stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,600

Previous 10,600 -0.0%

Holding current value

Previous $12,000 16.67%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	BUY	$0.91 - $1.82 $5,239 - $10,479	5,758 Added 118.92%	10,600 $12,000
Q4 2022 Feb 01, 2023	SELL	$0.78 - $1.68 $591 - $1,273	-758 Reduced 13.54%	4,842 $1,000
Q1 2022 Apr 20, 2022	BUY	$1.61 - $5.2 $1,288 - $4,160	800 Added 16.67%	5,600 $18,000
Q4 2021 Jan 19, 2022	BUY	$2.87 - $6.29 $6,314 - $13,838	2,200 Added 84.62%	4,800 $15,000
Q3 2021 Oct 28, 2021	BUY	$4.91 - $9.07 $3,928 - $7,256	800 Added 44.44%	2,600 $26,000
Q2 2021 Aug 04, 2021	SELL	$7.82 - $13.8 $6,256 - $11,040	-800 Reduced 30.77%	1,800 $12,000
Q1 2021 May 05, 2021	BUY	$13.0 - $19.34 $10,400 - $15,472	800 Added 44.44%	2,600 $39,000
Q4 2020 Jan 15, 2021	BUY	$13.03 - $17.09 $13,030 - $17,090	1,000 Added 125.0%	1,800 $29,000
Q3 2020 Oct 27, 2020	SELL	$12.67 - $23.19 $6,335 - $11,595	-500 Reduced 38.46%	800 $11,000
Q2 2020 Jul 14, 2020	BUY	$12.52 - $23.45 $6,260 - $11,725	500 Added 62.5%	1,300 $27,000
Q1 2020 May 11, 2020	BUY	$11.4 - $27.28 $9,120 - $21,824	800 New	800 $13,000

Others Institutions Holding BCEL

# of Institutions

Shares Held

30.6K

Call Options Held

Put Options Held

Gofen & Glossberg LLC

20K
Shares

$0
0.0% of portfolio

View Full List

About Atreca, Inc.

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

More about BCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Endurance Wealth Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Endurance Wealth Management, Inc. with notifications on news.

Account

Endurance Wealth Management, Inc. Atreca, Inc. Transaction History